Jay S. Stout
Chief Technology OfficerDr. Jay S. Stout, Ph.D., M.S. is Chief Technology Officer of Immunovant, Inc. from April 2023. From 2020 to April 2023, he was an independent consultant supporting the scale up and validation of late stage products in immunology and cell and gene therapy. From June 2018 to January 2021, he led Technical Operations at Immunomedics (Gilead Sciences) leading to the approval of an antibody drug conjugate for oncology. Prior to that, he held various senior leadership roles in Technical Operation at Versartis (Aravive), San Bio, Merck, Amgen, Pfizer and BioNebraska (Restoragen). He has served on the Amgen Center for BioProcessing Advisory Board at the Keck Graduate Institute for more than a decade and was the Chair of the Advisory Board from 2021-2023. He received a BS and MS from the university of Lowa and PhD in Biochemistry & Chemistry from University of Nebraska - Lincoln.
Positions
- Company NameImmunovant, Inc.Stock CodeIMVTPositionChief Technology Officer
